Medication Description: Glibutid (Glibutidum)
Synonyms: Adebit, Silubin, Adebit, Buformin hydrochloride, Buformini hydrochloridum, Butylbiguanid, Butylnite, Gliporal, Glybigid hydrochloride, Krebon, Silubin, etc.
White crystalline powder bitter taste. Easily soluble in water and alcohol.
It refers to synthetic oral hypoglycemic (antidiabetic) drugs of the biguanide group.
The greatest hypoglycemic effect occurs within 4 to 5 hours after taking the drug.
Applied for the treatment of type II diabetes in adults. In combination with insulin, it is used for insulin-resistant diabetes, as well as for resistance to antidiabetic drugs sulfonylurea, for non-severe forms of diabetes, accompanied by obesity, and in patients receiving insulin treatment, with a labile course of diabetes.
Glibutid, like other biguanides (metformin, etc.), refers to oral antidiabetic drugs that cause a significant reduction in body weight in diabetic patients suffering from obesity. These drugs reduce appetite, increase anaerobic glycolysis, decrease glucose absorption from the gastrointestinal tract, and have anti-lipid and fibrinolytic effects.
Assign inside with food. As an antidiabetic agent take, starting with 0.1 g per day (50 mg in the morning and evening); Depending on the change in glucose in the blood and urine, the dose can be gradually increased by 50 mg per day, but the daily dose should not exceed 300 mg.
Maintenance doses are usually 50-100 mg in the morning and 50 mg in the evening.
When combined with insulin, the dose of the latter is gradually reduced under the control of glucose in the blood and urine.
Together with sulfonylurea preparations, glybutid is prescribed in cases when the first fails to reduce hyperglycemia and glucosuria to the required level.
In the complex treatment of obesity, glybutides are usually taken at a rate of 0.1 g per day (often in combination with anorexigenic drugs).
Glibutid is well tolerated, however, there may be loss of appetite, nausea, vomiting, diarrhea, metallic taste in the mouth. At a later date from the start of treatment (a month or more), weakness and weight loss are possible.
Side effects usually pass quickly with dose reduction or drug withdrawal.
Contraindications to the use of glybutide are: absolute indications for the use of insulin, the absence of endogenous (or exogenous) insulin in the body, comatose conditions, acidosis, infectious diseases, albuminuria on the basis of diabetic nephropathy, liver damage, diabetic angiopathy with the possibility of inflammation, gangrene of lesions pregnancy